Answer
Yes, people receiving Symtuza may still develop opportunistic infections and other complications of HIV infection, so they should remain under close clinical observation by physicians experienced in treating HIV-associated diseases.
Sources for this answer
- Symtuza 800 mg/150 mg/200 mg/10 mg film coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 17Document updated
Sources checked